genz-682452
Modify Date: 2025-08-27 13:04:47
genz-682452 structure
|
Common Name | genz-682452 | ||
|---|---|---|---|---|
| CAS Number | 1401090-53-6 | Molecular Weight | 389.487 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C20H24FN3O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of genz-682452Ibiglustat (Venglustat) is an inhibitor of glucosylceramide synthase extracted from patent WO 2015089067 A1, compound example 64. |
| Name | venglustat |
|---|---|
| Synonym | More Synonyms |
| Description | Ibiglustat (Venglustat) is an inhibitor of glucosylceramide synthase extracted from patent WO 2015089067 A1, compound example 64. |
|---|---|
| Related Catalog | |
| In Vivo | Ibiglustat is in phase II clinical trials for the treatment of Fabry's disease. Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy[2]. Substrate reduction therapy is an approach that reduces the synthesis of lipids reaching the lysosome through inhibition of glucosylceramide synthase (GCS)[1]. |
| References |
[1]. WO 2015089067 A1 [2]. Schiffmann R, et al. Fabry disease. Handb Clin Neurol. 2015;132:231-48. |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C20H24FN3O2S |
| Molecular Weight | 389.487 |
| Exact Mass | 389.157318 |
| LogP | 4.13 |
| Index of Refraction | 1.613 |
| Storage condition | 2-8℃ |
|
Name: Inhibition of N-terminal 6-his tagged TEV fused full length human NTMT1 (1 to 222 res...
Source: ChEMBL
Target: N-terminal Xaa-Pro-Lys N-methyltransferase 1
External Id: CHEMBL5318633
|
|
Name: Cytotoxicity counterscreen for inhibitors of SARS-CoV-2 cell entry
Source: NCGC
Target: N/A
External Id: TRND-SARS-CoV-2-cytotox-48hr
|
|
Name: Primary qHTS to identify inhibitors of SARS-CoV-2 cell entry
Source: NCGC
External Id: TRND-SARS-CoV-2-PP
|
|
Name: Inhibition of METTL21A (unknown origin) at 10 uM
Source: ChEMBL
Target: Protein N-lysine methyltransferase METTL21A
External Id: CHEMBL5119834
|
|
Name: Inhibition of human recombinant N-terminal his-tagged MLL1 (3745 to 3969 residues) ex...
Source: ChEMBL
Target: Histone-lysine N-methyltransferase 2A
External Id: CHEMBL5119835
|
|
Name: Inhibition of human recombinant N-terminal his-tagged MLL2 (5319 to 5537 residues) ex...
Source: ChEMBL
Target: Histone-lysine N-methyltransferase 2D
External Id: CHEMBL5119836
|
|
Name: Inhibition of human recombinant N-terminal his-tagged MLL3 (4689 to 4911 residues) ex...
Source: ChEMBL
Target: Histone-lysine N-methyltransferase 2C
External Id: CHEMBL5119837
|
|
Name: Inhibition of human recombinant N-terminal FLAG-tagged EZH1 (2 to 747 residues) expre...
Source: ChEMBL
Target: Histone-lysine N-methyltransferase EZH1
External Id: CHEMBL5119830
|
|
Name: Inhibition of human recombinant N-terminal FLAG-tagged EZH2 (2 to 746 residues) at 10...
Source: ChEMBL
Target: Histone-lysine N-methyltransferase EZH2
External Id: CHEMBL5119831
|
|
Name: Inhibition of human recombinant G9a expressed in Escherichia coli at 10 uM
Source: ChEMBL
Target: Histone-lysine N-methyltransferase EHMT2
External Id: CHEMBL5119832
|
Total 148, Current Page 1 of 15
1
2
3
4
5
| (3S)-1-Azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-2-propanyl}carbamate |
| Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester |
| MFCD28502073 |
| venglustat |
| Ibiglustat |
| genz-682452 |
| Ansofaxine Hydrochloride |